Replimune’s melanoma success looks more than skin deep

Replimune’s oncolytic virus RP1 is looking like a decent prospect for approval in melanoma following initial data from Ignyte, a mid-stage, though potentially registrational, study.

Even better news for investors is that these data have read-through to another trial, testing RP1 plus Libtayo in a different cancer, with some industry watchers believing Replimune’s asset could be the go-to product when anti-PD-1 therapy has failed. The stock closed up 22% yesterday, allowing the group to launch a $125m fundraising.